• 1
    Bauduer F, Ducout L. Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent. J Thromb Haemost 2004; 2: 0000 .
  • 2
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 16915.
  • 3
    Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 154651.
  • 4
    Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2: 2427.
  • 5
    Ørstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89101.
  • 6
    De Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001; 357: 1015.
  • 7
    James PD, Notley CR, Cameron C, O'Brien LA, Hegadorn CA, Berber E, Hough C, Rivard GE, Lillicrap D. The spectrum of phenotype/genotype associations in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. Blood 2003; 102: 89a.
  • 8
    Eikenboom JCJ, Van Marion V, Putter H, Gomez Garcia EB, Peake I, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habert D, Holmberg L, Lethagen S, Pasi J, Hill F. Analysis of cosegregation of type 1 von Willebrands disease phenotype and von Willebrand factor gene haplotypes in the European Multicenter MCMDM-1VWD study. Blood 2003; 102: 90a.
  • 9
    Souto JC, Almasy L, Soria JM, Buil A, Stone W, Lathrop M, Blangero J, Fontcuberta J. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003; 89: 46874.
  • 10
    O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002; 116: 3506.
  • 11
    De Visser MC, Sandkuijl LA, Lensen RP, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 2003; 1: 17716.
  • 12
    Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 208993.
  • 13
    Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991; 65: 23741.
  • 14
    Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 16074.
  • 15
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 4549.
  • 16
    Castaman G, Eikenboom JCJ, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand Disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999; 82: 106570.
  • 17
    Manzano CRC, Iriondo M, Mazon LI, Vicario A, Aguirre A. Structuring the genetic heterogeneity of the Basque population: a view from classical polymorphisms. Hum Biol 2002; 74: 5174.
  • 18
    Weiss HJ. The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation. J Thromb Haemost 2004; 2: 1989.
  • 19
    Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; DOI 10.1182/blood-2004-01-0349 .
  • 20
    Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 31415.
  • 21
    Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 7318.
  • 22
    Van Der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, Van Der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 2004; 124: 3437.
  • 23
    Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 1525.
  • 24
    Goodeve A, Walker M, Peake I, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Lethagen S, Pasi J, Hill F. Contribution of ABO blood group to type 1 von Willebrand disease in patients entered in the multicenter MCMDM-1VWD study. Blood 2003; 102: 91a.